Familial aggregation of leukemia is rare. In some families, however, a clear segregation of the predisposition to leukemia is observed. A prime example is familial platelet disorder in which the affected individuals exhibit an enhanced risk to develop acute myeloid leukemia (FPD/AML). This condition is characterized by thrombocytopenia, platelet dysfunction and a 35% lifetime risk for developing leukemia.
1 FPD/AML is caused by germline mutations in RUNX1. 2 The encoded RUNX1 protein contains a highly conserved Runt domain, which is involved in both DNA binding and heterodimerization with its partner protein, CBFb. Together these proteins form a transcription factor complex that is widely expressed in various hematopoietic lineages and regulates the expression of several critical genes.
Proband III:4 of family 1 (Figure 1a ) was a 9-year-old male. He developed AML (karyotype: 47,XY, þ 8) at the age of 7 years without a previous detection of thrombocytopenia. His treatment was complicated by long lasting thrombocytopenia. Two years after treatment the boy was in complete remission with a platelet count of 132 Â 10 9 /l. His grandfather (I:1) developed non-Hodgkin lymphoma at the age of 49 years and died 2 years later. His treatment was complicated by thrombocytopenia as well. Subsequent family studies revealed that all children of I:1 suffered from a moderate thrombocytopenia, with platelet counts varying from 50 to 100 Â 10 9 /l. There was no history of spontaneous bleeding in the family. The father of the proband (II:6) had a platelet count of 103 Â 10 9 /l at the age of 44 years and his brother (III:3) a count of 63 Â 10 9 /l at the age of 16 years. This latter brother was screened for thrombocytopenia shortly after birth, showing normal platelet counts. At the age of 4 years he underwent tonsillectomy and was tested again, revealing a moderate thrombocytopenia. In 2007, he had a period of recurrent epistaxis, but otherwise there was no bleeding history. The platelet count of his sister (III5), screened at age 11, was normal (247 Â 10 9 /l). RUNX1 sequence analysis failed to detect a mutation in the DNA of the proband. However, genome wide copy number analysis using a 500K SNP array (Affymetrix, Inc., Santa Clara, Figure 1 Characterization of the RUNX1 intragenic duplication in family 1. (a) Pedigree of family 1. Family members tested for the presence of the RUNX1 duplication are indicated by þ (mutation present), or À (mutation absent). (b) Schematic presentation of the copy number profile of the RUNX1 genomic region at 21q22.12, performed in the proband of family 1 using a custom-made ultra-high-density oligonucleotide array, and the RUNX1 gene and protein structure. A copy number gain on chromosome 21q22.12 (35 127-35 293 Mb) was identified, with the genomic breakpoints located in introns 1 and 6 of the RUNX1 gene, thereby including the exons 2-6 encoding the Runt domain. (c) PCR-based amplification using alternate combinations of the four primers (depicted in b) located around the breakpoint region revealed the orientation of the duplicated region. In the proband a combination of primers F2 and R1 resulted in a product (n) that was not present in control DNA, which is consistent with a tandem duplication in a head-to-tail orientation in the proband. Sequence analysis of the F2R1 fragments revealed that both breakpoints were located within Alu-repetitive elements. (d) The duplication-specific F2R1 product was used for further segregation analysis in the family, revealing that the father (II6) and the brother (III3), but not the sister (III5) of the proband, were carrier of the intragenic RUNX1 duplication. The primers developed for sequence analysis of exon 6 were used as control (C).
Letters to the Editor CA, USA) revealed a 162 kb duplication in chromosome 21q22.12, encompassing part of the RUNX1 gene. Further characterization of this duplication by an ultra-highdensity custom-made oligonucleotide array (NimbleGen Systems, Madison, WI, USA) revealed its exact boundaries, located in introns 1 and 6 of the RUNX1 gene, respectively ( Figure 1b ). As intragenic duplications may affect the wild-type allele if integrated in tandem, we decided to more precisely determine the size, location and orientation of the duplicated segment. To this end, several combinations of forward and reverse primers were made, located on either side of the duplication. Through primers F2 and R1 a polymerase chain reaction (PCR) product was generated, consistent with a tandem duplication in a head-to-tail orientation (Figures 1b and c) . Sequence analysis of the amplified fragment confirmed this conclusion and revealed that both breakpoints are located within Alu-repetitive elements, suggesting Alu-Alu-mediated non-allelic homologous recombination as a mechanism for the formation of the duplication. Although the duplicated exons are inserted in-frame, it is likely that a duplication of this size and location affects the Runt domain and the Transactivation domain of RUNX1 and, as such, is likely to interfere with a proper functioning of the protein.
The duplication-specific PCR assay with primers F2 and R1 was subsequently used for further segregation analysis in the family. A PCR assay developed for sequence analysis of exon 6 was used as internal control (Figure 1d (140 Â 10 9 /l) at the age of 3 years, without bleeding diathesis. The grandmother of the proband (I:2) developed AML (M5) at the age of 35 years and died 1 year later. The mother (II:1) of the proband had no complaints, but was diagnosed with thrombocytopenia (100 Â 10 9 /l) as well. Family studies revealed additional relatives with thrombocytopenia or thrombocytopathy, including an uncle (II:2) of the proband who had a mild bleeding diathesis and thrombocytopenia (100 Â 10 9 /l) with prolonged closure times on platelet function analyzer (PFA-100; epinephrine) testing (4300 s compared with o165 s in normal individuals). The mean platelet volume was normal. His two daughters (III:3 and III:4), 5-and 3-years old, respectively, had no bleeding diathesis, but also suffered from mild thrombocytopenias (100-140 Â 10 9 /l). Thrombopoietin was normal in all individuals. Another uncle (II:3) of the proband also had a mild bleeding diathesis and a mild thrombocytopenia (100-150 Â 10 9 /l). PFA-100 (epinephrine) testing revealed a closure time of 275 s (nl. o165 s). The mean platelet volume was normal. His son (III:5, 6-years old) had no bleeding diathesis and had a normal platelet count.
After sequence analysis failed to yield any mutation, a heterozygous genomic deletion extending across exons 5 and 5b of RUNX1 was found by multiplex ligation-dependent probe amplification analysis (MLPA, MRC-Holland, Amsterdam, the Netherlands) in the germline DNA of III:1 (Figure 2b ). Two cousins (III:3 and III:4) were also screened by MLPA and found to be carriers of the same deletion. Subsequently, we performed reverse transcriptase (RT)-PCR and sequencing on mRNA derived from bone marrow of the index patient using primers situated in exons 4 and 6 of the RUNX1 gene (Figure 2c) . Control cDNA yielded a 389 bp band representing a transcript containing exon 5, but lacking exon 5b, suggesting that this latter exon is not present in the predominant RUNX1 transcript. In addition to the 389 bp wild-type band, the index patient Letters to the Editor displayed a 284 bp band representing a transcript lacking exon 5 (105 bp) (Figure 2d) . Sequencing confirmed the identity of these transcripts. The mutant transcript results in an in-frame deletion of 35 amino acids that disrupts part of the Runt homology domain and domains reported to bind the coactivators p300/CBP and corepressor Sin3A. 4 Owing to its limited resolution and the small size of the deletion, this aberration was not detected by whole genome SNP array on DNA derived from bone marrow of the proband, which did show a trisomy of chromosome 21. This trisomy has targeted the mutant allele as the deletion in the index patient was detected in two of the three copies of chromosome 21 (Figure 2b ). Both myelodysplastic bone marrow and blood from the proband (III:1) were negative for FLT3 internal tandem duplication mutations, a highly frequent mutation in AML (results not shown). 5 Furthermore, no other potentially pathogenic copy number variations were detected in the germline of this patient.
Both families presented with thrombocytopenia and patients with hematologic malignancies. The diagnosis FPD/AML syndrome was made only after the occurrence of a second case with AML/MDS. We expect that families presenting with only thrombocytopenia may escape diagnosis and, therefore, that a leukemic rate of 35% may be an overestimation. The variable penetrance and clinical heterogeneity seen in FPD/AML can partially be explained by recruitment of different secondary alterations. 6 Furthermore, it was shown earlier that a markedly higher rate of leukemia can be seen in families carrying RUNX1 mutations that act in a dominant-negative manner, as compared with families harboring RUNX1 mutations that result in haploinsufficiency. 7 The mutations identified in this study are expected to result in haploinsufficiency, which may explain the mild phenotypes and the low incidences of leukemia observed. On the basis of our findings we believe that the clinical detection rate of FPD/AML can be improved by considering the diagnosis FPD/AML in families with autosomal dominant thrombocytopenia with and without AML. Furthermore, in children with unexplained mild thrombocytopenia and/or platelet dysfunction, the parents should be screened for thrombocytopenia to reveal a possible hereditary component. An inquiry for symptoms of a bleeding diathesis is insufficient, as was shown in family 2.
In several families reported in the literature, siblings have acted as stem cell transplantation donors before their identification as carriers of RUNX1 mutations, 1, 8 Therefore, the recognition of FPD/AML, including its molecular cause, is of prime importance. Great care should be given to ensure that a nonaffected family member will be selected as donor.
The median age of onset of leukemia in FPD/AML families is 33 years, with the earliest presentation in a 6-year-old child. 1 The index patient in family 2 was 5-years old when she was diagnosed with MDS. The proband in family 1 was a child as well. This indicates that FPD/AML is a syndrome that deserves special attention by pediatric hematologists.
Recently, Owen et al. found RUNX1 mutations in 5 out of 10 families with a history of more than one first degree relative with MDS/AML. 1 Further analysis of these families revealed several family members with symptomatic or asymptomatic thrombocytopenia, thus fulfilling the clinical diagnosis of FPD/AML. Quantitative analysis of RUNX1 was not performed in the study of Owen et al., suggesting that even more families in this cohort might have been affected by FPD/AML.
The copy number variations in RUNX1 reported here remained undetected using direct sequencing alone, and were only identified after using genomic arrays and MLPA, respectively. Among the first FPD/AML families reported, one family harbored an intragenic RUNX1 deletion that was not identified by sequence analysis. 2 This publication now means that 3/27 published FPD/AML families carry RUNX1 deletions and/or insertions. Our unpublished data raise this number to 4/34 (Carmichael, Wilkins, Scott et al., unpublished). However, concerning the mild thrombocytopenia in these families, and lower incidence of MDS/AML, this may be an underestimate. We conclude that mutation analysis of RUNX1, and hence the identification of FPD/AML syndrome, can be refined by complementing the analysis with a quantitative method. For this purpose MLPA may be used, as this is a sensitive and costeffective technique for the detection of whole or partial gene deletions and/or duplications.
Taken together, we conclude that the identification of RUNX1 mutation carriers can be improved at both the clinical and the molecular level. To this end, the diagnosis FPD/AML should be considered in families with autosomal dominant thrombocytopenia, with or without AML. In addition, genomic screening for whole or partial gene deletions and duplications should be included in the RUNX1 mutation analysis.
Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells Telomeres are the capping structures of chromosome ends and are composed of repeated DNA sequences (B10 kb in adult somatic cells) and a specific set of associated proteins. The regulation of telomere length results from the action of telomerelengthening mechanisms, such as the telomerase complex (hTERT, hTR and dyskerin), and of telomere-shortening mechanisms, such as replication and recombination. Telomerase activity is regulated in cis by the shelterin hexa-protein complex (TRF1, TRF2, hRAP1, POT1, TIN2 and TPP1) and epigenetic factors. 1, 2 Proteins involved in DNA replication and repair are also associated in telomeric structure and function. 2 The shortening of telomere sequences upon cell divisions in most somatic cells results in irreversible cell growth arrest called senescence or in apoptosis. A change in telomere function is one of the main mechanisms underlying the evolution and maintenance of cancer cells. Telomere erosion may be critical in tumour suppression as it impairs cell proliferation. In many cancer cells, this is circumvented by reactivating the expression and/or activity of telomerase or by homologous recombination. 1, 2 Chronic lymphocytic leukaemia (CLL) is a B-cell malignancy with increased incidence among the elderly. The disease is due to an imbalance between cell death and proliferation resulting in an accumulation of malignant cells in the bone marrow and peripheral blood (reviewed in Van Bockstaele et al.
3 ). Clinically, the disease varies from indolent, which may progress to/or appear at diagnostic as an aggressive incurable form. The most commonly used biological markers for the disease outcome are the type of chromosomal aberration and the mutational status of immunoglobulin heavy-chain variable region genes (IgV H ), often associated with the expression status of Zap70 tyrosine kinase (reviewed in Van Bockstaele et al.
3 ). The telomere length and telomerase activity are further prognostic markers as unfavourable disease was associated with short telomeres 4 (reviewed in Van Bockstaele et al. 3 ). This, together with altered expression of several telomeric components, 5 indicates that telomeres are profoundly rearranged in CLL cells.
A subgroup of CLL cells is resistant to DNA damage-induced apoptosis in vitro (reviewed in Bouley et al. 6 ) and patients harbouring these cells inevitably develop the aggressive form of disease, suggesting that this is a clinically relevant factor. Here, we investigated whether specific telomere alterations can distinguish CLL cells sensitive (CLL-S) or resistant (CLL-R) to DNA damage-induced apoptosis in vitro. A total of 35 patients were included in this study (16 CLL-R and 19 CLL-S, clinical and biological behaviours were presented in Table 1 ). Southern blot analysis showed a significant difference in telomere length between the two subgroups of patients (Figure 1a) . The mean telomere length was twofold shorter (U-test, Po0.001) in CLL-R compared with the CLL-S (3552 ± 1151 bp for CLL-R and 8010 ± 1668 bp for CLL-S) (Figure 1b) . Furthermore, we observed a positive correlation (R 2 ¼ 0.675) between telomere restriction fragment length and the in vitro sensitivity to apoptosis (Figure 1c ) that appeared independent of previous clinical treatment of patients (Figures 1c and d) . The use of the Spearman's rank correlation showed that this association was significant (Po0.0001). These results clearly show that resistant CLL cells have shorter telomeres than sensitive CLL cells. The mRNA level of hTERT was assessed by quantitative PCR analysis and revealed no significant difference (U-test, P40.05) between the two subgroups of patients (Figure 2a) . We also analyzed the mRNA level of the negative regulator of the telomerase, PinX1, by quantitative PCR analysis in samples already included in the analysis for the expression of hTERT. No significant difference (U-test, P40.05) was observed between the two subgroups of cells (Figure 2b ). Telomere maintenance and protection mainly depends on the presence of the six shelterin components and their stoichiometry at chromosome ends is crucial for telomere
